SUPPRESSION OF THE HUMORAL IMMUNE RESPONSE BY CANNABINOIDS IS PARTIALLY MEDIATED THROUGH INHIBITION OF ADENYLATE CYCLASE BY A PERTUSSIS TOXIN-SENSITIVE G-PROTEIN COUPLED MECHANISM

NORBERT E. KAMINSKI,*† WOO S. KOH,‡ KYU H. YANG,‡ MICHAEL LEE‡
and FAY K. KESSLER§

*Department of Pharmacology and Toxicology and Department of Pathology, Michigan State
University, East Lansing, MI 48824; ‡Department of Life Science, Korea Advanced Institute of
Science and Technology, Seoul, Korea; and §Department of Pharmacology and Toxicology, Medical
College of Virginia/Virginia Commonwealth University, Richmond, VA 23298, U.S.A.

Abstract—Cannabinoid compounds, including the major psychoactive component of marihuana, Δ^9-tetrahydrocannabinol (Δ^9-THC), have been widely established as being inhibitory on a broad array of humoral and cell-mediated immune responses. The presence of cannabinoid receptors has been identified recently on mouse spleen cells, which possess structural and functional characteristics similar to those of the G-protein coupled cannabinoid receptor originally identified in rat brain. These findings, together with those demonstrating that Δ^9-THC inhibits adenylate cyclase in splenocytes, strongly suggest that certain aspects of immune inhibition by cannabinoids may be mediated through a cannabinoid receptor-associated mechanism. The objective of the present studies was to determine whether inhibition of adenylate cyclase is relevant to mouse spleen cell immune function and, if so, whether this inhibition is mediated through a G_i-protein coupled mechanism as previously described in neuronal tissue. Spleen cell activation by the phorbol ester phorbol-12-myristate-13-acetate (PMA), plus the calcium ionophore ionomycin, produced a rapid but transient increase in cytosolic cAMP, which was inhibited completely by immunosuppressive concentrations of Δ^9-THC (22 μM) and the synthetic bicyclic cannabinoid CP-55940 (5.2 μM), which produced no effect on cell viability. Inhibition by cannabinoids of lymphocyte proliferative responses to PMA plus ionomycin and the sheep erythrocyte (sRBC) IgM antibody-forming cell (AFC) response, was abrogated completely by low concentrations of dibutyryl-cAMP (10–100 μM). Inhibition of the sRBC AFC response by both Δ^9-THC (22 μM) and CP-55940 (5.2 μM) was also abrogated by preincubation of splenocytes for 24 hr with pertussis toxin (0.1–100 ng/mL). Pertussis toxin pretreatment of spleen cells was also found to directly abrogate cannabinoid inhibition of adenylate cyclase, as measured by forskolin-stimulated accumulation of intracellular cAMP. These results indicate that inhibition of the sRBC AFC response by cannabinoids is mediated, at least in part, by inhibition of adenylate cyclase through a pertussis toxin-sensitive G_i-protein coupled cannabinoid receptor. Additionally, these studies further support the premise that cAMP is an important mediator of lymphocyte activation.

Key words: cannabinoids; immunosuppression; pertussis toxin-sensitive; adenylate cyclase/cAMP signal transduction

The mechanism by which cannabinoid compounds produce their broad spectrum of physiologic effects has been attributed historically to disruption of cell membrane processes through nonspecific intercalation of these highly lipophilic molecules into the lipid bilayer. In contrast to this view, a number of compelling lines of evidence have been forthcoming from studies primarily using neuronal tissue preparations and CNS-associated responses that implicate the role of a receptor-mediated mechanism for cannabinoid-induced effects. First, cannabinoids display stereoselective activity [1–6], a hallmark of receptor-mediated mechanisms. Second, can-

nabinoid receptor radioligands exhibit a high degree of specific binding to neuronal tissue preparations [2, 5, 7, 8]. Third, cannabinoids markedly inhibit adenylate cyclase in neuronal tissue preparations [9–13]. The recent isolation and cloning of a G-protein coupled cannabinoid receptor (CB1) from a rat brain cDNA library, taken together with previous indirect evidence, confirm the existence of cannabinoid receptors in association with the CNS [4]. In addition to direct effects on the CNS, cannabinoids have also been found to produce a variety of changes in peripheral non-CNS tissues of which the best characterized to date have been the testis and immune system. Interestingly, cannabinoid receptor mRNA has been identified in both tissues.

Recent studies in our laboratory have focused on characterizing the mechanisms by which cannabinoids modulate immunocompetence. Various animal and

* Corresponding author: Dr. Norbert E. Kaminski,
Department of Pharmacology and Toxicology, B-330 Life
Sciences Bldg., Michigan State University, East Lansing,
MI 48824. Tel. (517) 353-3786; FAX (517) 353-8915.

cell culture model systems have been utilized in past investigations to demonstrate that cannabinoids markedly inhibit humoral, cell-mediated and innate immune responses [reviewed in Ref. 14]. Although the mechanism responsible for these effects on immunocompetence has been elusive, recent identification of functional cannabinoid receptors on mouse spleen cells represents additional evidence suggesting that cannabinoid physiologic effects are, at least in part, mediated through a highly specific receptor-associated mechanism [15]. This conclusion was based on the following observations: demonstration by the synthetic cannabinoid receptor ligand [³H]CP-55940* of a high degree of specific and saturable binding (greater than 60%) to mouse splenocytes exhibiting a K_d in the picomolar range; stereoselective inhibition of IgM AFC response using a variety of cannabinoid enantiomers including CP-55940/CP-56667; and the detection of cannabinoid receptor mRNA transcripts by RT-PCR [15]. The role of cannabinoid receptors in immune modulation is further supported by the fact that Δ^9-THC markedly inhibits adenylate cyclase activity in splenocytes [16], the same signal transduction pathway by which signalling through the cannabinoid receptor has been shown to occur in neuronal tissue preparation. Recently, further evidence has been forthcoming supporting the expression of cannabinoid receptors on lymphoid cells. Bouaboula and coworkers [17] reported the expression of cannabinoid receptors and CB1 mRNA transcripts on a variety of human leukocyte cell lines, as well as in primary human lymphoid cells. Most recently, Munro and coworkers [18] identified a cannabinoid receptor subtype, CB2, in the marginal zone of human spleen, which exhibits approximately 44% homology with the cannabinoid receptor originally identified in brain. Interestingly, the degree of homology between these two receptors increases to approximately 68% for those transmembrane residues proposed to confer ligand specificity. Radioligand binding analysis demonstrated that classic cannabinoid receptor ligands exhibit similar binding affinity for CB2 as previously reported for the brain receptor, CB1, with the exception of cannabinol, which has a higher affinity for the CB2. Interestingly, this novel peripheral cannabinoid receptor was not detected in brain tissue preparations.

Although the existence of cannabinoid receptors on lymphoid cells has been widely established, the relative distribution of CB1 and CB2 on lymphoid cells is unclear. Furthermore, it is also unclear how changes in signalling via the adenylate cyclase/cAMP second messenger pathway following cannabinoid ligand–receptor interactions alter normal physiologic

processes. The implication that inhibition of adenylate cyclase by cannabinoids in mouse spleen cells may represent a critical biochemical event in mediating immune suppression by cannabimimetic agents is contrary to a generally held view that the adenylate cyclase/cAMP second messenger system is responsible for down-regulating immunological responses [see review in Ref. 19]. However, results from the present studies strongly suggest that the cAMP-mediated signal transduction pathway is critical to lymphocyte function. The objective of the present studies was to determine whether inhibition of adenylate cyclase by cannabimimetic agents is functionally relevant for lymphocyte function as measured by the sRBC AFC response and, if so, whether this inhibition is mediated through a G_i-protein coupled mechanism.

MATERIALS AND METHODS

Chemicals. Δ^9-THC was provided by the National Institute on Drug Abuse. CP-55940 and CP-56667 were gifts from Dr. Lawrence Melvin (Pfizer, Inc., Groton, CT).

Mice. Virus-free female B6C3F1 mice, 5–6 weeks of age, were purchased from the Frederick Cancer Research Center. On arrival, mice were randomized, transferred to plastic cages containing saw dust bedding (4 mice per cage), and quarantined for 1 week. Mice were given food (Purina Certified Laboratory Chow) and water *ad lib.* and were not used for experimentation until their body weight was 17–20 g. Animal-holding rooms were kept at 21–24° and 40–60% relative humidity with a 12-hr light/dark cycle.

cAMP determinations. Single spleen cell suspensions were prepared from naive female B6C3F1 mice. The cells were washed once with RPMI 1640 and centrifuged at 800 g for 10 min to form a pellet. EBSS without HEPES containing 5% NBCS at 1 mL/spleen in addition to Gey's solution was added to the cell pellet. The solution was swirled on ice for 5 min to lyse red blood cells. The remaining intact spleen cells were pelleted by centrifugation at 1600 g for 15 min, and the supernatant containing the lysates was discarded. The cells were washed twice in EBSS without HEPES buffer and adjusted to 1×10^7 cells/mL in RPMI containing 1% NBCS. These cells were then used for either temporal addition studies with PMA and ionomycin or to study the pertussis toxin sensitivity of the cAMP response. For the temporal addition studies, 1-mL aliquots of the isolated cells were transferred to 12×75 mL glass tubes, and 100 μM IBMX (Sigma, St. Louis, MO) was added to all of the cell treatment groups with the exception of appropriate controls (i.e. naive, vehicle). Following a 10-min incubation at 37°, cells were treated with either vehicle (1% DMSO), Δ^9-THC (22 μM) or CP-55940 (5.2 μM) and incubated for an additional 10 min at 37°. The cell preparations were then stimulated with PMA (80 nM) and ionomycin (1 μM) for 0.5 to 10 min. In the second series of cAMP experiments, the cells were treated with various concentrations of pertussis toxin (0.1 to 100 ng/mL) for 24 hr at 37°. Aliquots 1 mL of both the pertussis toxin-treated and

---

* Abbreviations: Δ^9-THC, Δ^9-tetrahydrocannabinol; sRBC, sheep erythrocytes; G-protein, guanine-nucleotide-binding protein; PMA, phorbol-12-myristate-13-acetate; Bt₂cAMP, dibutyryl-cAMP; RPMI 1640, Roswell Park Memorial Institute 1640; AFC, antibody-forming cell; NBCS, new born calf serum; EBSS, Earle's balanced salt solution; CP-55940/CP-56667, −/ + *cis*-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-*trans*-4-(3-hydroxypropyl)-cyclohexanol; IBMX, 3-isobutyl-1-methylxanthine; and RT-PCR, reverse transcription-polymerase chain reaction.

untreated cell suspensions were transferred to glass tubes followed by the addition of 100 μM IBMX to all of the cell treatment groups with the exception of appropriate controls (i.e. naive, vehicle and forskolin alone). Following a 10-min incubation at 37°, cells were treated with either vehicle (1% DMSO), Δ⁹-THC (22 μM) or CP-55940 (5.2 μM) and incubated for an additional 5 min at 37°. The cell preparation was then stimulated with 50 μM forskolin (Sigma) for 15 min. After the stimulation with either PMA + ionomycin or forskolin, adenylate cyclase was inactivated by the addition of the cAMP extraction buffer: acidic ethanol (1 mL 1 of N HCl/ 100 mL EtOH). The cells were subsequently disrupted by sonication to facilitate the release of intracellular cAMP into the extraction buffer. The solution containing the cell lysate was centrifuged at 1600 g for 15 min to remove any remaining cell fragments, and the supernatants were collected and lyophilized. The samples were stored at −20° prior to quantitation of cAMP. Aliquots of reconstituted lyophilized cell lysates were quantitated for cAMP using a cAMP assay kit (Diagnostic Products Inc., Los Angeles, CA). This method is based on the competition between unlabeled cAMP and a fixed quantity of ³H-labeled cAMP for binding to a protein that has a high specificity and affinity for cAMP, which mimics the regulatory subunit of protein kinase A. The amount of the ³H-labeled cAMP protein complex formed is inversely related to the amount of unlabeled cAMP present in the assay sample. The concentration of cAMP in test samples was determined by comparison with a linear standard curve.

In vitro *antibody assays*. Spleens from untreated mice were isolated aseptically and made into a single cell suspension. The spleen cell suspension was adjusted to 1.0×10^7 cells/mL in RPMI 1640 supplemented with 5% NBCS (Hyclone, Logan, UT), 2 mM L-glutamine, antibiotic-antimycotic (100 units penicillin, 100 μg streptomycin and 0.25 μg amphizone/mL) (GIBCO, Grand Island, NY), and 5×10^{-5} M 2-mercaptoethanol (complete RPMI medium). When the effects of pertussis toxin were being studied, spleen cells were incubated at 37° for 24 hr in the presence or absence (control cells) of pertussis toxin (0.1 to 100 ng/mL). Following the preincubation step, cells were washed free of pertussis toxin, resuspended in complete RPMI at a density of 1.0×10^7 cells/mL, and transferred in 500-μL aliquots to a 48-well Costar culture plate (Cambridge, MA). Cultures were set up in quadruplicate for each treatment group. Δ⁹-THC (22 μM) or CP-55940 (5.2 μM) was added directly in 5 μL of vehicle (DMSO, 0.01% final culture concentration) to the respective wells of the 48-well culture plate just prior to antigen sensitization. For the Bt₂cAMP studies, Bt₂cAMP (10–250 μM) was added directly to spleen cell cultures immediately after cannabinoid treatment and before antigen sensitization. Each well was sensitized with 5×10^6 sRBC and cultured for 5 days in a Bellco stainless steel tissue culture chamber pressurized to 50 psi with a gas mixture consisting of 10% O₂, 7% CO₂ and 83% N₂. The culture chamber was maintained continuously rocking, on a rocker


Fig. 1. Inhibition of adenylate cyclase in PMA plus ionomycin-stimulated mouse splenocytes by Δ⁹-THC and CP-55940. Spleens from naive female B6C3F1 mice were isolated and made into a single cell suspension. Splenocytes were washed and adjusted to 5×10^6 cells/mL and transferred in 1-mL aliquots to 12×75 mm glass tubes. Spleen cells were incubated with 100 μM IBMX for 10 min and then treated with either Δ⁹-THC (22 μM) or CP-55940 (5.2 μM) for 10 min followed by a 0.5 to 10-min stimulation with PMA (80 nM) + ionomycin (1 μM). Intracellular cAMP concentrations (pmol) are expressed as the means ± SEM of triplicate samples, as determined for each group, from one of three representative experiments. Key: (*) $P < 0.05$ as compared with the IBMX control group (determined by Dunnett's t-test).

platform, for the duration of the culture period (i.e. 5 days). Enumeration of the AFC response was performed as previously described [20]. Briefly, spleen cells were resuspended in each well of the 48-well culture plate. A 50-μL aliquot of cell suspension was removed from each well and added to a 12×75 mm heated glass culture tube containing 400 μL of 0.5% melted agar (DIFCO, Detroit, MI) solution in EBSS and 0.05% DEAE-Dextran (Pharmacia, Piscataway, NJ). Additionally, each agar tube received 25 μL of guinea pig complement and 25 μL of indicator sRBC. The tubes were immediately vortex mixed, a 200-μL aliquot of the mixture was transferred to a 100×15 mm petri dish, and the agar solution was covered with a 25×50 mm microscope cover slip. Once the agar solidified, the petri dishes were incubated at 37° for 3 hr. Following the 3-hr incubation, the AFC were enumerated at 6.5 magnification using a Bellco plaque viewer. During the 3-hr incubation period, the number of spleen cells per well and viability (described below in "Pronase determination of viability") were determined using a Coulter Counter. Results from quadruplicate cultures were expressed as the mean AFC/10⁶ recovered splenocytes ± SEM.

Pronase determination of viability. Aliquots of spleen cell suspensions were incubated with an equal volume (100 μL) of pronase (5 mg/mL) (Calbiochem-Behring Corp., San Diego, CA) for 10 min at 37°. Following the incubation, the splenocyte solution was diluted with 10 mL Isoton® (Coulter, Addison, NJ), counted on a Coulter counter, and compared with a 100-μL aliquot of the same test sample of

Fig. 2. Reversal of Δ^9-THC- and CP-55940-mediated inhibition of adenylate cyclase by pertussis toxin. Spleens from naive (NA) female B6C3F1 mice were isolated and made into a single cell suspension. Splenocytes were washed and adjusted to 5×10^6 cells/mL and aliquoted into 15-mL polypropylene tubes. Both naive and vehicle groups were left untreated for 18 hr at 37°, while the treatment groups were incubated with pertussis toxin (0.1 to 100 ng/mL) for 18 hr at 37°. Cells were transferred in 1-mL aliquots to 12×75 mm glass tubes. Spleen cells were incubated with 100 μM IBMX for 10 min and then treated with either vehicle (VH; 0.01% DMSO), Δ^9-THC or CP-55940 for 5 min followed by a 15-min stimulation with forskolin. Intracellular cAMP concentrations (pmol) are expressed as the means $\pm$ SEM of triplicate samples, as determined for each group, from one of three representative experiments. Pertussis toxin (10 ng/mL) $\pm$ IBMX + forskolin control treatment group = 5.9 ± 1.2 pmol cAMP/5×10^6 spleen cells. Key: (*) $P < 0.05$ as compared with the IBMX + forskolin control group (determined by Dunnett's t-test).

splenocytes without pronase. The percent viability = (cell counts with pronase/cell counts without pronase) $\times$ 100.

Lymphoproliferation with PMA plus ionomycin. Splenocytes were isolated aseptically from untreated mice and adjusted to 5×10^6 cells/mL in complete RPMI 1640 and transferred in 200-μL aliquots to a 96-well flat bottom microtiter plate (Costar, Cambridge, MA). Quadruplicate cultures were treated with either vehicle (0.01% DMSO), Δ^9-THC (22 μM) or CP-55940 (5.2 μM). The splenocytes were treated with PMA (80 nM) and ionomycin (1 μM) and incubated at 37° and 5% CO_2 for 72 hr. Splenocytes were pulsed with 1 μCi/well of [³H]-thymidine for the last 16 hr of culture. Tritium incorporation was measured by scintillation counting.

Statistical analysis of data. The mean $\pm$ SEM was determined for each treatment group of a given experiment. The homogeneity of the results was determined using Bartlett's test for homogeneity [21]. Homogeneous data were evaluated by a parametric analysis of variance. When significant differences occurred, treatment groups were compared with the vehicle controls using a Dunnett's

two-tailed t-test [22]. Nonhomogeneous data were evaluated for significance using Wilcoxon's rank test [23].

RESULTS

Cannabinoid inhibition of adenylate cyclase activation in PMA plus ionomycin-stimulated lymphocytes. Activation of lymphocytes by concomitant treatment with PMA plus ionomycin produced a rapid but transient enhancement of cellular cAMP, which began at approximately 30 sec following cell activation, attained a maximum concentration at 3 min (4- to 5-fold increase), and returned to basal concentrations at approximately 10 min (Fig. 1). This increase in cellular cAMP following PMA plus ionomycin stimulation was inhibited completely by both Δ^9-THC (22 μM) and CP-55940 (5.2 μM), cannabinoid concentrations that have no effect on cell viability. The rationale for utilizing PMA plus ionomycin as an activation stimulus for these studies was that it allowed for an almost instantaneous and synchronized activation of the spleen cell preparation

Fig. 3. Reversal of Δ^9-THC-mediated inhibition of the *in vitro* sRBC IgM AFC response by dibutyryl cAMP. Spleens from naive (NA) female B6C3F1 mice were isolated and made into a single cell suspension. Splenocytes were washed and adjusted to 1×10^7 cells/mL and transferred in 500-µL aliquots to the wells of a 48-well culture plate. Quadruplicate cultures were prepared with vehicle (VH; 0.01% DMSO) or Δ^9-THC (22 µM), then treated with dibutyryl cAMP (10–250 µM) and, last, sensitized with sRBC. Cultures were subsequently assayed using sRBC for their day 5 IgM antibody response by enumerating the number of antibody-forming cells (AFC). The bars represent the means ± SEM, as determined for each group, from one of four representative experiments. Key: (*)P < 0.05 as compared with the vehicle group (determined by Dunnett's *t*-test).


Fig. 4. Reversal of CP-55940-mediated inhibition of the *in vitro* sRBC IgM AFC response by dibutyryl cAMP. Spleens from naive (NA) female B6C3F1 mice were isolated and made into a single cell suspension. Splenocytes were washed and adjusted to 1×10^7 cells/mL and transferred in 500-µL aliquots to the wells of a 48-well culture plate. Quadruplicate cultures were prepared with vehicle (VH; 0.01% DMSO) or CP-55940 (5.2 µM), then treated with dibutyryl cAMP (10–250 µM) and, last, sensitized with sRBC. Cultures were subsequently assayed using sRBC for their day 5 IgM antibody response by enumerating the number of antibody-forming cells (AFC). The bars represent the means ± SEM, as determined for each group, from one of four representative experiments. Key: (*) P < 0.05 as compared with the vehicle group (determined by Dunnett's *t*-test).

and eliminated potential confounding effects by by-passing external receptors.

Effect of pertussis toxin pretreatment of spleen cells on cannabinoid-induced inhibition of cellular cAMP. Inhibition of adenylate cyclase by cannabinoid has been reported in a variety of cell preparations [10, 13, 24–26], including cannabinoid receptor-transfected CHO cells [4] and mouse spleen cells [5]. In cell membranes isolated from NG108-15 neuroblastoma X glioma hybrid cells and in N18TG2 neuroblastoma cells, this inhibition was found to be pertussis toxin sensitive, implicating the involvement of G_i [11]. *Bordetella pertussis* (pertussis toxin) acts by adding ADP-ribose to the α subunit of G_i. In this case, $G_{i\alpha}$ linked to ADP-ribose cannot inhibit adenylate cyclase [reviewed in Refs. 27 and 28]. As observed in neuroblastoma cells, inhibition of adenylate cyclase by cannabinoids in spleen cells was also reversed by a 24-hr pretreatment with pertussis toxin (Fig. 2). The most effective uncoupling of the cannabinoid receptor, as measured by adenylate cyclase activity, occurred at low pertussis toxin concentrations (0.1 ng/mL). An interesting aside to this series of experiments was the observation that 22 µM Δ^9-THC and 5.2 µM CP-55940 produced comparable inhibition of adenylate cyclase activity. In previously reported findings, we observed that 22 µM Δ^9-THC and 5.2 µM CP-55940 also produce comparable inhibition of the sRBC AFC response [5].

Reversal by cAMP of cannabinoid-mediated

inhibition of the sRBC IgM AFC response and PMA plus ionomycin-induced splenocyte proliferation. The functional relevance of adenylate cyclase in lymphoid cells has been enigmatic. The studies described in Fig. 1 showed a rapid rise in cAMP shortly following lymphocyte activation, which was inhibited almost completely by Δ^9-THC (22 µM) and CP-55940 (5.2 µM) at concentrations that have been shown previously to inhibit a variety of immunological responses [15, 16, 29]. In an attempt to assess whether this cannabinoid-mediated inhibition of adenylate cyclase has functional relevance, studies were performed to determine whether inhibition by Δ^9-THC and CP-55940 of the sRBC AFC response and proliferative responses to PMA plus ionomycin could be reversed by experimentally increasing the cellular cAMP concentration using the membrane-permeable cAMP analog Bt_2cAMP. PMA plus ionomycin was used as an activation stimulus because it allowed for an almost instantaneous and synchronized activation of the spleen cell preparation. Concentrations of both Δ^9-THC (22 µM) and CP-55940 (5.2 µM), which were found previously to inhibit markedly both the IgM AFC response and lymphocyte proliferative responses [15, 16, 29], were utilized for these present studies. A relatively broad concentration response was performed with

Fig. 8. Reversal of Δ^9-THC-mediated inhibition of the *in vitro* sRBC IgM AFC response by pertussis toxin. Spleens from naive (NA) female B6C3F1 mice were isolated and made into a single cell suspension. Splenocytes were washed and adjusted to 1×10^7 cells/mL and aliquoted into 15-mL polypropylene tubes. Both naive and vehicle groups were left untreated for 18 hr at 37°, while the treatment group was incubated with pertussis toxin (0.1 to 100 ng/mL) for 18 hr at 37°. Cells were transferred in 500-μL aliquots to the wells of a 48-well culture plate, and quadruplicate cultures were prepared with vehicle (VH; 0.01% DMSO) or Δ^9-THC (22 μM) and sensitized with sRBC. Cultures were subsequently assayed using sRBC for their day 5 IgM antibody response by enumerating the number of antibody-forming cells (AFC). The bars represent the means $\pm$ SEM, as determined for each group, from one of three representative experiments. Key: (*) $P < 0.05$ as compared with the vehicle group (determined by Dunnett's *t*-test).

Fig. 9. Reversal of CP-55940-mediated inhibition of the *in vitro* sRBC IgM AFC response by pertussis toxin. Spleens from naive (NA) female B6C3F1 mice were isolated and made into a single cell suspension. Splenocytes were washed and adjusted to 1×10^7 cells/mL and aliquoted into 15-mL polypropylene tubes. Both naive and vehicle groups were left untreated for 18 hr at 37°, while the treatment group was incubated with pertussis toxin (0.1 to 100 ng/mL) for 18 hr at 37°. Cells were transferred in 500-μL aliquots to the wells of a 48-well culture plate, and quadruplicate cultures were prepared with vehicle (VH; 0.01% DMSO) or CP-55940 (5.2 μM) and sensitized with sRBC. Cultures were subsequently assayed using sRBC for their day 5 IgM antibody response by enumerating the number of antibody-forming cells (AFC). The bars represent the means $\pm$ SEM, as determined for each group, from one of three representative experiments. Key: (*) $P < 0.05$ as compared with the vehicle group (determined by Dunnett's *t*-test).

the fact that the PKC inhibitor chelerythrine abrogated the activation of PKC by PMA–ionomycin treatment (unpublished observation). Similar bursts in cellular cAMP following mitogenic stimulation of lymphocytes have been reported by others [32–34]. Conversely, spleen cells activated with PMA plus ionomycin in the presence of cannabinoids do not exhibit this rise in cellular cAMP due to the inhibition of adenylate cyclase. This has also been demonstrated in Δ^9-THC-treated splenocytes following activation with the diterpene forskolin [16]. These findings suggest that a rapid increase in cellular cAMP may be a critical signal transduction event during lymphocyte activation.

Establishing a direct link between rapidly occurring biochemical changes associated with signal transduction events and functional changes, which in many cases require several days such as cytokine secretion, proliferation or the production of antibody, is extremely difficult. The findings from this series of studies represent the first step in establishing such a link between the inhibition of adenylate cyclase in spleen cells by cannabinoids and a loss of immune function. It is important to emphasize that, although by no means confirmatory, several critical observations from these studies support this premise. Biochemically, the present findings clearly establish that cannabinoids almost completely abrogated the

rapid rise in intracellular cAMP which follows activation of splenocytes with phorbol ester and calcium ionophore. Similar results were obtained following forskolin stimulation, a diterpene which directly activates the enzyme, and is therefore indicative that cannabinoids inhibit activation of adenylate cyclase. Equally important is the fact that pretreatment of spleen cells with pertussis toxin reversed the inhibitory effects produced by cannabinoids on adenylate cyclase activity. This pertussis toxin sensitivity is not unique to splenocytes and has been reported by others in other experimental model systems in characterizing the cannabinoid receptor [4, 11, 35]. Taken together, these results suggest that cannabinoids inhibit the intracellular rise of cAMP during lymphocyte activation through the inhibition of adenylate cyclase by a pertussis toxin-sensitive mechanism, most likely involving G_i.

In an attempt to correlate the functional significance of these biochemical changes, an initial and basic premise tested was that if inhibition of cellular cAMP was, in fact, critical to spleen cell function, immune inhibition by cannabinoids should be reversed in the presence of Bt_2cAMP or 8-Br-cAMP, membrane-permeable cAMP analogs. Interestingly, cannabinoid inhibition of both the spleen cell proliferative responses to PMA plus

ionomycin as well as the sRBC antibody response was, in fact, reversed by low concentrations of cAMP analogs (10–50 μM). Additionally, temporal addition studies revealed that the reversal of the sRBC response by exogenous cAMP was restricted to the first 30 min following antigen sensitization. It is important to emphasize that although PMA plus ionomycin treatment of spleen cells clearly induced a very rapid increase in cellular cAMP within 3 min, this activation signal is virtually instantaneous, by-passing cell surface receptors and activating all spleen cells simultaneously. In contrast, lymphocyte activation in response to antigen sensitization by sRBC is slower and dependent on antigen processing and presentation by antigen presenting cells prior to lymphocyte activation. Under this second condition, lymphocyte activation obviously would not be synchronized such that all cells would not be activated in unison instantaneously following sRBC sensitization. With this in mind, although the kinetics of the sRBC AFC response reversal by Bt$_2$cAMP are slightly different than what would be expected for reversal of the PMA plus ionomycin proliferative response, nonetheless, the findings are in agreement and further support the premise that inhibition of adenylate cyclase by cannabinoids affects an early cAMP-dependent lymphocyte activation event. The temporal addition studies are especially significant in that although they measure a response requiring 5 days, nonetheless they clearly indicate that cAMP is critical to events occurring during the first 30 min following antigen sensitization. Further evidence supporting the role of adenylate cyclase inhibition in mediating at least some aspects of immunosuppression by cannabinoids was the finding that as with forskolin-stimulated cellular cAMP accumulation, pertussis toxin reversed the inhibitory influences associated with either Δ^9-THC or CP-55940 on the sRBC AFC response.

Although the present studies strongly suggest that the inhibition of certain immune responses by Δ^9-THC and structurally related cannabinoids is mediated through inhibition of adenylate cyclase activity, which results in a depletion of the cytosolic cAMP pool in splenocytes, there currently exist two opposing views ascribed to the functional role of the adenylate cyclase/cAMP second messenger system with respect to lymphocytes. One view supports the premise that cAMP is an early but transient signal associated with lymphocyte activation. This is consistent with numerous studies including our own, which clearly demonstrate that early during lymphocyte activation there occurs a modest 2- to 5-fold transient enhancement of cytosolic cAMP that can persist up to approximately 30 min after the initial activating signal [32–34]. This enhancement in cellular cAMP has been shown by others to be accompanied by corresponding protein kinase A (PKA)-associated phosphorylation events in which the greatest magnitude of PKA-mediated phosphorylation also occurs during the first 30 min following lymphocyte activation [36]. Related to this observation has been the finding that low concentrations of Bt$_2$cAMP (0.1 to 10 μM) induce the same degree of lymphocyte RNA synthesis as that induced by the T-cell lectin phytohemagglutinin

[36]. Conversely, Bt$_2$cAMP at concentrations in excess of 100 μM markedly inhibit RNA synthesis. A second but opposing view is that cAMP is a strong inhibitory signal in lymphocytes. This is supported by studies in which membrane-permeable cAMP analogs added directly to activated lymphocyte cultures were found to inhibit markedly cell cycle progression. Both B- and T-cells have been shown to be arrested in transition from G$_1$ to S phase following experimental elevation of cytosolic cAMP: in T-cells by high concentrations of cAMP analogs, 250–500 μM [37], or in B-cells following stimulation with the diterpene adenylate cyclase activator, forskolin [38]. It is important to emphasize that, on closer examination of the results, the findings are not contradictory but describe different modulatory effects for cAMP at different times during cell cycle progression and at different cyclic nucleotide concentrations. Without exception, even those studies that support the role of cAMP as being an important intracellular mediator of lymphocyte activation have demonstrated clearly that high nonphysiologically relevant concentrations of cAMP (in excess of 100 μM) produce marked inhibition of various cellular processes, and can be mimicked in vitro with membrane-permeable cAMP analogs [36].

Much confusion still exists pertaining to the role of the adenylate cyclase/cAMP signal transduction pathway in lymphocyte activation and function. Nonetheless, the present results clearly demonstrate that inhibition of lymphocyte proliferation or the IgM sRBC AFC response by both Δ^9-THC and CP-55940 is accompanied by a marked inhibition of adenylate cyclase activity in spleen cells. This inhibition can be abrogated effectively by restoring cytosolic cAMP with micromolar concentrations of membrane-permeable cAMP analogs or in the case of the sRBC response, through the inactivation of G$_{i\alpha}$ by pertussis toxin. These findings, together with the kinetics of splenocyte inhibition by cannabinoids and the kinetics associated with the reversal of inhibition by exogenous cAMP, strongly support the role of a G$_i$-protein coupled cannabinoid receptor that, upon ligand-receptor binding, inhibits adenylate cyclase activity which, in turn, blocks the conversion of ATP to cAMP, an obligatory signal transduction event during lymphocyte activation.

REFERENCES

1. Howlett AC, Johnson MR, Melvin LS and Milne GM, Nonclassical cannabinoid analgetics inhibit adenylate cyclase: Development of a cannabinoid receptor model. *Mol Pharmacol* 33: 297–302, 1988.
2. Devane WA, Dysarz FA, Johnson MR, Melvin LS and Howlett AC, Determination and characterization of a cannabinoid receptor in rat brain. *Mol Pharmacol* 34: 605–613, 1988.
3. Little PJ, Compton DR, Johnson MR, Melvin LS and Martin BR, Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. *J Pharmacol Exp Ther* 247: 1046–1051, 1988.
4. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI, Structure of a cannabinoid receptor

48:10-C

and functional expression of the cloned cDNA. *Nature* **346**: 561–564, 1990.

5. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR and Rice KC, Cannabinoid receptor localization in brain. *Proc Natl Acad Sci USA* **87**: 1932–1936, 1990.

6. Gérard CM, Mollereau C, Vassart G and Parmentier M, Molecular cloning of a human cannabinoid receptor which is also expressed in testis. *Biochem J* **279**: 129–134, 1991.

7. Harris LS, Carchman RA and Martin BR, Evidence for the existence of specific cannabinoid binding sites. *Life Sci* **22**: 1131–1138, 1978.

8. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R and Ward SJ, Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. *Pharmacol Biochem Behav* **40**: 471–478, 1991.

9. Howlett AC and Fleming RM, Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. *Mol Pharmacol* **26**: 532–538, 1984.

10. Howlett AC, Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. *Mol Pharmacol* **27**: 429–436, 1985.

11. Howlett AC, Qualy JM and Khachatrian LL, Involvement of G_i in the inhibition of adenylate cyclase by cannabimimetic drugs. *Mol Pharmacol* **29**: 307–313, 1986.

12. Howlett AC, Cannabinoid inhibition of adenylate cyclase: Relative activity of constituents and metabolites of marihuana. *Neuropharmacology* **26**: 507–512, 1987.

13. Bidaut-Russell M and Howlett AC, Cannabinoid receptor-regulated cyclic AMP accumulation in the rat striatum. *J Neurochem* **57**: 1769–1773, 1991.

14. Munson AE and Fehr KO, Immunological effects of cannabis. In: *Adverse Health and Behavioral Consequences of Cannabis Use* (Eds. Fefr KO and Kalant H), Working papers for the ARS-WHO Scientific Meetings, pp. 257–353. Addiction Research Foundation, Toronto, 1983.

15. Kaminski NE, Abood ME, Kessler FK, Martin BR and Schatz AR, Identification of a functionally relevant cannabinoid receptor on mouse spleen cells involved in cannabinoid-mediated immune modulation. *Mol Pharmacol* **42**: 736–742, 1992.

16. Schatz AR, Kessler FK and Kaminski NE, Inhibition of adenylate cyclase by Δ⁹-tetrahydrocannabinol in mouse spleen cells: A potential mechanism for cannabinoid-mediated immunosuppression. *Life Sci* **51**: PL25–PL30, 1992.

17. Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G and Casellas P, Cannabinoid-receptor expression in human leukocytes. *Eur J Biochem* **214**: 173–180, 1993.

18. Munro S, Thomas KL and Abu-Shaar M, Molecular characterization of peripheral receptor for cannabinoids. *Nature* **365**: 61–65, 1993.

19. Kammer GM, The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. *Immunol Today* **9**: 222–229, 1988.

20. Kaminski NE and Holsapple MP, Inhibition of macrophage accessory cell function in casein-treated B6C3F1 mice. *J Immunol* **139**: 1804–1810, 1987.

21. Bartlett MS, Sub-sampling for attributes. *J Roy Stat Soc* (Suppl) **4**: 131, 1937.

22. Dunnett CW, A multiple comparison procedure for comparing several treatments with a control. *J Am Stat Assoc* **50**: 1096–1121, 1955.

23. Gross AJ and Clark VA (Eds.), Gehan–Wilcoxon test. In: *Survival Distributions: Reliability Applications in the Biomedical Sciences* pp. 102–123. John Wiley, New York, 1975.

24. Heindel JJ and Keith WB, Specific inhibition of FSH-stimulated cAMP accumulation by Δ⁹-tetrahydrocannabinol in cultures of rat Sertoli cells. *Toxicol Appl Pharmacol* **101**, 124–134, 1989.

25. Rowley JT and Rowley PT, Tetrahydrocannabinol inhibits adenylate cyclase in human leukemia cells. *Life Sci* **46**: 217–222, 1989.

26. Little PJ and Martin BR, The effects of Δ⁹-tetrahydrocannabinol and other cannabinoids on cAMP accumulation in synaptosomes. *Life Sci* **48**, 1133–1141, 1991.

27. Gilman AG, G proteins: Transducers of receptor-generated signals. *Annu Rev Biochem* **56**: 615–649, 1987.

28. Scott JD, Cyclic nucleotide-dependent protein kinase. *Pharmacol Ther* **50**: 123–145, 1991.

29. Schatz AR, Koh WS and Kaminski NE, Δ⁹-tetrahydrocannabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function. *Immunopharmacology* **26**: 129–137, 1993.

30. Gérard CM, Mollereau C, Vassart G and Parmentier M, Nucelotide sequence of a human cannabinoid receptor cDNA. *Nucleic Acids Res* **18**: 7142, 1990.

31. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A and Mechoulam R, Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* **258**: 1946–1949, 1992.

32. Smith JW, Steiner AL, Newberry WM and Parker CW, Cyclic adenosine 3′,5′-monophosphate in human lymphocytes. Alteration after phytohemagglutinin. *J Clin Invest* **50**: 432–441, 1971.

33. Hadden JW, Hadden EM, Haddox MK and Goldberg ND, Guanosine 3′:5′-cyclic monophosphates: A possible intracellular mediator of mitogenic influences in lymphocytes. *Proc Natl Acad Sci USA* **69**: 3024–3027, 1972.

34. Russell DH, Type I cyclic AMP-dependent protein kinase as a positive effector of growth. *Adv Cyclic Nucleotide Res* **9**: 493–506, 1978.

35. Bidaut-Russell M, Devane WA and Howlett AC, Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. *J Neurochem* **55**: 21–26, 1990.

36. Cross ME and Ord MG, Changes in histone phosphorylation and associated early metabolic events in pig lymphocyte cultures transformed by phytohaemagglutinin or 6-N,2′-O-dibutyryladenosine 3′:5′-cyclic monophosphate. *Biochem J* **124**: 241–248, 1971.

37. Johnson KW, Davis BH and Smith KA, cAMP antagonizes interleukin 2-promoted T-cell cycle progression at a discrete point in early G_1. *Proc Natl Acad Sci USA* **83**: 6072–6076, 1988.

38. Muraguchi A, Miyazaki K, Kehrl JH and Fauci AS, Inhibition of human B cell activation by diterpine forskolin: Interference with B cell growth factor-induced G_1 to S transition of the B cell cycle. *J Immunol* **133**: 1283–1287, 1984.